Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4220 Risk of bowel ischemia in patients with mesenteric neuroendocrine tumors after treatment with 177Lutetium-DOTATATE

Introduction: 177Lutetium (Lu)-DOTATATE is an effective treatment for metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). However, radiation can cause transient inflammation/swelling of tumors which can result in toxicity. Treatment-related small bowel obstruction associated with mesenteric or peritoneal disease has been described.

Conference:

Presenting Author:

Authors: Pelle E, Al-Toubah T, El-Haddad G, Strosberg J,

Keywords: PRRT, Acute bowel ischemia, mesenteric metastasis,

#3777 The value of the Patient Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE) in patients with neuroendocrine tumors (NET) treated with 177Lutetium-DOTATATE (177Lu)

Introduction: The correlation between clinical benefit and toxicity is an unmet need in daily clinical practice. PRO-CTCAE is a questionnaire that allows subjective and detailed symptom reporting directly from patients. This prospective, multicentre study will apply PRO-CTCAE in a cohort of consecutive adult patients with metastatic NET on treatment with 177Lu.

Conference:

Presenting Author: Hernando J

Authors: Carmona Alonso A, Hernando Cubero J, Garcia Alvarez A, Roca-Herrera M, Garcia Burillo A,

Keywords: TNE, 177Lu, PRO-CTCAE,

#2753 Risk of PRRT-Associated Bowel Obstruction in Patients with Mesenteric/Peritoneal Disease and Potential Role of Corticosteroids in Treatment

Introduction: Although radiation-induced mesenteritis or peritonitis can potentially exacerbate risk of bowel obstruction, there are no data in the literature on incidence of intestinal obstruction related to peptide receptor radiotherapy (PRRT)

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Al-Toubah T, El-Haddad G, Pelle E, Strosberg J,

Keywords: PRRT, Lutetium-dotatate, Bowel obstruction, Peritoneal carcinomatosis, Steroids,

#2120 One Year Experience with Lutetium-DOTATATE for Disseminated NETs in the Gregorio Marañon Hospital

Introduction: The main curative therapy for NET is surgical resection when the disease is localized. But high percentage of patients is diagnosed with advanced disseminated disease and the peptide receptor radionuclide therapy (PRRT) with somatostatin analogs (SSA) is an emerging effective treatment.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Picallo P

Authors: Picallo M, Percovich J, García Centeno R, Rotger A, Colon A,

Keywords: Neuroendocrine, Lutetium, Radionuclide therapy,

#287 Lutetium-177 DOTATATE Therapy in the Management of Neuroendocrine Tumors

Introduction: Peptide receptor radionuclide therapy (PRRT) is a specific targeted treatment for NETs expressing somatostatin receptors. 177Lu-DOTATATE is one of several newly available compounds for this treatment.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Carroll R, Tan T, Todd J, Al-Nahhas A, Bomanji J,

Keywords: 177Lutetium-DOTATATE therapy, neuroendocrine tumor, paraganglioma, SDHB,